Skip to main content
Top
Published in: Inflammation 3/2012

01-06-2012

Vasoactive Intestinal Peptide Enhances TNF-α-Induced IL-6 and IL-8 Synthesis in Human Proximal Renal Tubular Epithelial Cells by NF-κB-Dependent Mechanism

Authors: Ling Huang, Yiting Tang, Jiao Qin, Yu Peng, Qiongjing Yuan, Fangfang Zhang, Lijian Tao

Published in: Inflammation | Issue 3/2012

Login to get access

Abstract

Vasoactive intestinal polypeptide (VIP) is a 28-amino acid neuropeptide with vasodilator, bronchodilator, and anti-inflammatory effects. But little is known about its pro-inflammatory effects. We investigated the effect of VIP on the secretion of interleukin-6 (IL-6) and interleukin-8 (IL-8), two pro-inflammatory cytokines, in TNF-α-activated proximal renal tubular epithelial cell line (HK-2 cells). Cultured HK-2 cells were treated with TNF-α in the presence or absence of VIP with a dose range from 1 to 100 nM, followed by analysis of pro-inflammatory cytokines (IL-6 and IL-8) induction and their signal events including activation of the NF-κB pathway. We report here that tumor necrosis factor-α (TNF-α) increased IL-6 and IL-8 production, and that these effects were potentiated by VIP at 10 nM in HK-2 cells. However, VIP at 1 and 100 nM did not display this function. Consistent with these observations, we were able to show that VIP at 10 nM upregulated TNF-α-induced phosphorylation of IκB-α, leading to IκB-α degradation and the subsequent nuclear translocation of NF-κB. Furthermore, VIP-enhanced activation of NF-κB transcription activity was demonstrated using a NF-κB reporter construct upon transient transfection into HK-2 cells. These results strongly suggest that VIP synergistically enhances TNF-α-stimulated IL-6 and IL-8 synthesis via activating the NF-κB pathway in HK-2 cells.
Literature
1.
go back to reference Silverstein, D.M., et al. 2003. Altered expression of immune modulator and structural genes in neonatal unilateral ureteral obstruction. Kidney International 64(1): 25–35.PubMedCrossRef Silverstein, D.M., et al. 2003. Altered expression of immune modulator and structural genes in neonatal unilateral ureteral obstruction. Kidney International 64(1): 25–35.PubMedCrossRef
2.
go back to reference Noronha, I.L., C.K. Fujihara, and R. Zatz. 2002. The inflammatory component in progressive renal disease—Are interventions possible? Nephrology, Dialysis, Transplantation 17: 363–368.PubMedCrossRef Noronha, I.L., C.K. Fujihara, and R. Zatz. 2002. The inflammatory component in progressive renal disease—Are interventions possible? Nephrology, Dialysis, Transplantation 17: 363–368.PubMedCrossRef
3.
go back to reference Li, Z.I., A.C. Chung, L. Zhou, X.R. Huang, F. Liu, P. Fu, J.M. Fan, A.J. Szalai, and H.Y. Lan. 2011. C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Laboratory Investigation 91(6): 837–851.PubMedCrossRef Li, Z.I., A.C. Chung, L. Zhou, X.R. Huang, F. Liu, P. Fu, J.M. Fan, A.J. Szalai, and H.Y. Lan. 2011. C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Laboratory Investigation 91(6): 837–851.PubMedCrossRef
4.
go back to reference Wang, P.H., M.A. Cenedeze, G. Campanholle, D.M. Malheiros, H.A. Torres, J.B. Pesquero, A. Pacheco-Silva, and N.O. Camara. 2009. Deletion of bradykinin B1 receptor reduces renal fibrosis. International Immunopharmacology 9: 653–657.PubMedCrossRef Wang, P.H., M.A. Cenedeze, G. Campanholle, D.M. Malheiros, H.A. Torres, J.B. Pesquero, A. Pacheco-Silva, and N.O. Camara. 2009. Deletion of bradykinin B1 receptor reduces renal fibrosis. International Immunopharmacology 9: 653–657.PubMedCrossRef
5.
go back to reference Allach, D., E.E. Varfolomeev, N.L. Malinin, Y.V. Goltsev, A.V. Kovalenko, and M.P. Boldin. 1999. Tumor necrosis factor receptor and Fas signaling mechanisms. Annual Review of Immunology 17: 331–367.CrossRef Allach, D., E.E. Varfolomeev, N.L. Malinin, Y.V. Goltsev, A.V. Kovalenko, and M.P. Boldin. 1999. Tumor necrosis factor receptor and Fas signaling mechanisms. Annual Review of Immunology 17: 331–367.CrossRef
6.
go back to reference Mas, S., R. Martínez-Pinna, J.L. Martín-Ventura, et al. 2010. Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes. Diabetes 59: 1292–1301.PubMedCrossRef Mas, S., R. Martínez-Pinna, J.L. Martín-Ventura, et al. 2010. Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes. Diabetes 59: 1292–1301.PubMedCrossRef
7.
go back to reference DeHaij, S., A.C. Bakker, R.N. Vander Geest, G. Haegeman, et al. 2005. NF-kappa B mediated IL-6 production by renal epithelial cells is regulated by c-jun NH2-terminal kinase. Journal of the American Society of Nephrology 16: 1603–1611.CrossRef DeHaij, S., A.C. Bakker, R.N. Vander Geest, G. Haegeman, et al. 2005. NF-kappa B mediated IL-6 production by renal epithelial cells is regulated by c-jun NH2-terminal kinase. Journal of the American Society of Nephrology 16: 1603–1611.CrossRef
8.
go back to reference Sengul, S., C. Zwizinski, and V. Batuman. 2003. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. American Journal of Physiology. Renal Physiology 284: F1245–F1254.PubMed Sengul, S., C. Zwizinski, and V. Batuman. 2003. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. American Journal of Physiology. Renal Physiology 284: F1245–F1254.PubMed
9.
go back to reference Bodanszky, M., Y.S. Klausner, and S.I. Said. 1973. Biological activities of synthetic peptides corresponding to fragments of and to the entire sequence of vasoactive intestinal peptide. Proceedings of the National Academy of Sciences of the USA 70: 382–384.PubMedCrossRef Bodanszky, M., Y.S. Klausner, and S.I. Said. 1973. Biological activities of synthetic peptides corresponding to fragments of and to the entire sequence of vasoactive intestinal peptide. Proceedings of the National Academy of Sciences of the USA 70: 382–384.PubMedCrossRef
10.
go back to reference Bryant, M.G., M.M. Polak, I. Modlin, S.R. Bloom, R.H. Albuquerque, and A.G. Pearse. 1976. Possible dual role for vasoactive intestinal peptide as gastrointestinal hormone and neurotransmitter substance. Lancet 1: 991–993.PubMedCrossRef Bryant, M.G., M.M. Polak, I. Modlin, S.R. Bloom, R.H. Albuquerque, and A.G. Pearse. 1976. Possible dual role for vasoactive intestinal peptide as gastrointestinal hormone and neurotransmitter substance. Lancet 1: 991–993.PubMedCrossRef
11.
go back to reference Abad, C., Y. Juarranz, C. Martinez, A. Arranz, F. Rosignoli, M. GarciaGomez, J. Leceta, and R.P. Gomariz. 2005. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflammatory Bowel Diseases 11: 674–684.PubMedCrossRef Abad, C., Y. Juarranz, C. Martinez, A. Arranz, F. Rosignoli, M. GarciaGomez, J. Leceta, and R.P. Gomariz. 2005. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflammatory Bowel Diseases 11: 674–684.PubMedCrossRef
12.
go back to reference Li, H., Y. Mei, Y. Wang, and L. Xu. 2006. Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. Journal of Clinical Immunology 26(5): 430–437.PubMedCrossRef Li, H., Y. Mei, Y. Wang, and L. Xu. 2006. Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. Journal of Clinical Immunology 26(5): 430–437.PubMedCrossRef
13.
go back to reference Leceta, J., R.P. Gomariz, C. Martinez, C. Abad, D. Ganea, and M. Delgado. 2000. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Annals of the New York Academy of Science 921: 92–102.CrossRef Leceta, J., R.P. Gomariz, C. Martinez, C. Abad, D. Ganea, and M. Delgado. 2000. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Annals of the New York Academy of Science 921: 92–102.CrossRef
14.
go back to reference Delgado, M., C. Abad, C. Martinez, J. Leceta, and R.P. Gomariz. 2001. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nature Medicine 7: 563–568.PubMedCrossRef Delgado, M., C. Abad, C. Martinez, J. Leceta, and R.P. Gomariz. 2001. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nature Medicine 7: 563–568.PubMedCrossRef
15.
go back to reference Juarranz, M.G., B. Santiago, M. Torroba, I. Gutierrez-Canas, G. Palao, M. Galindo, C. Abad, C. Martinez, J. Leceta, J.L. Pablos, and R.P. Gomariz. 2004. Vasoactive intestinal peptide modulates pro-inflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford, England) 43: 416–422.CrossRef Juarranz, M.G., B. Santiago, M. Torroba, I. Gutierrez-Canas, G. Palao, M. Galindo, C. Abad, C. Martinez, J. Leceta, J.L. Pablos, and R.P. Gomariz. 2004. Vasoactive intestinal peptide modulates pro-inflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford, England) 43: 416–422.CrossRef
16.
go back to reference Abad, C., C. Martinez, M.G. Juarranz, A. Arranz, J. Leceta, M. Delgado, and R.P. Gomariz. 2003. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology 124: 961–971.PubMedCrossRef Abad, C., C. Martinez, M.G. Juarranz, A. Arranz, J. Leceta, M. Delgado, and R.P. Gomariz. 2003. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn’s disease. Gastroenterology 124: 961–971.PubMedCrossRef
17.
go back to reference Toumi, F., M. Neunlist, M.G. Denis, T. Oreshkova, C.L. Laboisse, J.P. Galmiche, and A. Jarry. 2004. Vasoactive intestinal peptide induces IL-8 production in human colonic epithelial cells via MAP kinase-dependent and PKA-independent pathways. Biochemical and Biophysical Research Communications 317: 187–191.PubMedCrossRef Toumi, F., M. Neunlist, M.G. Denis, T. Oreshkova, C.L. Laboisse, J.P. Galmiche, and A. Jarry. 2004. Vasoactive intestinal peptide induces IL-8 production in human colonic epithelial cells via MAP kinase-dependent and PKA-independent pathways. Biochemical and Biophysical Research Communications 317: 187–191.PubMedCrossRef
18.
go back to reference Martinez, C., M. Delgado, et al. 1998. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: In vitro and in vivo studies. Journal of Neuroimmunology 85: 155–167.PubMedCrossRef Martinez, C., M. Delgado, et al. 1998. VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: In vitro and in vivo studies. Journal of Neuroimmunology 85: 155–167.PubMedCrossRef
19.
go back to reference Martinez, C., et al. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. Journal of Leukocyte Biology 63: 591–601.PubMed Martinez, C., et al. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. Journal of Leukocyte Biology 63: 591–601.PubMed
20.
go back to reference Natsume, H., H. Tokuda, J. Mizutani, S. Adachi, R. Matsushima-Nishiwaki, C. Minamitani, K. Kato, O. Kozawa, and T. Otsuka. 2010. Synergistic effect of vasoactive intestinal peptides on TNF-α-induced IL-6 synthesis in osteoblasts: Amplification of p44/p42 MAP kinase activation. International Journal of Molecular Medicine 25: 813–817.PubMed Natsume, H., H. Tokuda, J. Mizutani, S. Adachi, R. Matsushima-Nishiwaki, C. Minamitani, K. Kato, O. Kozawa, and T. Otsuka. 2010. Synergistic effect of vasoactive intestinal peptides on TNF-α-induced IL-6 synthesis in osteoblasts: Amplification of p44/p42 MAP kinase activation. International Journal of Molecular Medicine 25: 813–817.PubMed
21.
go back to reference Mullol, J., J.N. Baraniuk, M. Pitale, T. Benfield, C. Logun, C. Picado, and J.H. Shelhamer. 1997. Vasoactive intestinal peptide (VIP) induces IL-6 and IL-8, but not G-CSF and GM-CSF release from a human bronchial epithelial cell line. Neuropeptides 31(2): 119–124.PubMedCrossRef Mullol, J., J.N. Baraniuk, M. Pitale, T. Benfield, C. Logun, C. Picado, and J.H. Shelhamer. 1997. Vasoactive intestinal peptide (VIP) induces IL-6 and IL-8, but not G-CSF and GM-CSF release from a human bronchial epithelial cell line. Neuropeptides 31(2): 119–124.PubMedCrossRef
22.
go back to reference Persson, E., and U.H. Lerner. 2005. The neuropeptide VIP potentiates IL-6 production induced by pro-inflammatory osteotropic cytokines in calvarial osteoblastsand the osteoblastic cell line MC3T3-E1q. Biochemical and Biophysical Research Communications 335(3): 705–711.PubMedCrossRef Persson, E., and U.H. Lerner. 2005. The neuropeptide VIP potentiates IL-6 production induced by pro-inflammatory osteotropic cytokines in calvarial osteoblastsand the osteoblastic cell line MC3T3-E1q. Biochemical and Biophysical Research Communications 335(3): 705–711.PubMedCrossRef
23.
go back to reference Delgado, M., E.J. Munoz-Elias, R.P. Gomariz, and D. Ganea. 1999. VIP and PACAP prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and interferon regulatory factor 1 activation. Journal of Immunology 162(8): 4685–4696. Delgado, M., E.J. Munoz-Elias, R.P. Gomariz, and D. Ganea. 1999. VIP and PACAP prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-κB and interferon regulatory factor 1 activation. Journal of Immunology 162(8): 4685–4696.
24.
go back to reference Delgado, M., D. Pozo, C. Martinez, J. Leceta, J.R. Calvo, D. Ganea, and R.P. Gomariz. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: In vitro and in vivo studies. Journal of Immunology 162(4): 2358–2367. Delgado, M., D. Pozo, C. Martinez, J. Leceta, J.R. Calvo, D. Ganea, and R.P. Gomariz. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-α production by macrophages: In vitro and in vivo studies. Journal of Immunology 162(4): 2358–2367.
25.
go back to reference Delgado, M., E.J. Munoz-Elias, R.P. Gomariz, and D. Ganea. 1999. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages, subsequent effect on IFNc synthesis by T cells. Journal of Neuroimmunology 96(2): 167–181.PubMedCrossRef Delgado, M., E.J. Munoz-Elias, R.P. Gomariz, and D. Ganea. 1999. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages, subsequent effect on IFNc synthesis by T cells. Journal of Neuroimmunology 96(2): 167–181.PubMedCrossRef
26.
go back to reference Xin, Z., and S. Sriram. 1998. Vasoactive intestinal peptide inhibit IL-12 and nitric oxide production in murine macrophages. Journal of Neuroimmunology 89(1–2): 206–212.PubMedCrossRef Xin, Z., and S. Sriram. 1998. Vasoactive intestinal peptide inhibit IL-12 and nitric oxide production in murine macrophages. Journal of Neuroimmunology 89(1–2): 206–212.PubMedCrossRef
27.
go back to reference Delgado, M., W. Sun, J. Leceta, and D. Ganea. 1999. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. Journal of Immunology 163(8): 4213–4223. Delgado, M., W. Sun, J. Leceta, and D. Ganea. 1999. VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. Journal of Immunology 163(8): 4213–4223.
28.
go back to reference Delgado, M., E.J. Munoz-Elias, Y. Kan, I. Gozes, M. Fridkin, D.E. Brenneman, R.P. Gomariz, and D. Ganea. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit TNF-α transcriptional activation by regulating NF-κB and CREB/c-Jun. Journal of Biological Chemistry 273(47): 31427–31436.PubMedCrossRef Delgado, M., E.J. Munoz-Elias, Y. Kan, I. Gozes, M. Fridkin, D.E. Brenneman, R.P. Gomariz, and D. Ganea. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit TNF-α transcriptional activation by regulating NF-κB and CREB/c-Jun. Journal of Biological Chemistry 273(47): 31427–31436.PubMedCrossRef
29.
go back to reference Delgado, M., E.J. Munoz-Elias, R.P. Gomariz, and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide enhance IL-10 production by murine macrophages: In vitro and in vivo studies. Journal of Immunology 162(3): 1707–1716. Delgado, M., E.J. Munoz-Elias, R.P. Gomariz, and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide enhance IL-10 production by murine macrophages: In vitro and in vivo studies. Journal of Immunology 162(3): 1707–1716.
30.
go back to reference Delgado, M., and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappa B and Ets activation. Journal of Biological Chemistry 274(45): 31930–31940.PubMedCrossRef Delgado, M., and D. Ganea. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappa B and Ets activation. Journal of Biological Chemistry 274(45): 31930–31940.PubMedCrossRef
31.
go back to reference Delgado, M., and D. Ganea. 2001. Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Journal of Immunology 167: 966–975. Delgado, M., and D. Ganea. 2001. Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Journal of Immunology 167: 966–975.
32.
go back to reference Delgado, M., and D. Ganea. 2003. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochemical and Biophysical Research Communications 301(4): 825–832.PubMedCrossRef Delgado, M., and D. Ganea. 2003. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes. Biochemical and Biophysical Research Communications 301(4): 825–832.PubMedCrossRef
33.
go back to reference Delgado, M., and D. Ganea. 2003. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor B-dependent transcriptional activity. Biochemical and Biophysical Research Communications 302(2): 275–283.PubMedCrossRef Delgado, M., and D. Ganea. 2003. Vasoactive intestinal peptide inhibits IL-8 production in human monocytes by downregulating nuclear factor B-dependent transcriptional activity. Biochemical and Biophysical Research Communications 302(2): 275–283.PubMedCrossRef
34.
go back to reference Christophe, J. 1993. Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochimica et Biophysica Acta 1154: 183–199.PubMed Christophe, J. 1993. Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochimica et Biophysica Acta 1154: 183–199.PubMed
35.
go back to reference VanRampelbergh, J., P. Poloczek, I. Francoys, C. Delporte, J. Winand, P. Robberecht, and M. Waelbroeck. 1997. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochimica et Biophysica Acta 1357: 249–255.CrossRef VanRampelbergh, J., P. Poloczek, I. Francoys, C. Delporte, J. Winand, P. Robberecht, and M. Waelbroeck. 1997. The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins. Biochimica et Biophysica Acta 1357: 249–255.CrossRef
36.
go back to reference Vaudry, D., B.J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry. 2000. Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacological Reviews 52: 269–324.PubMed Vaudry, D., B.J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry. 2000. Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacological Reviews 52: 269–324.PubMed
37.
go back to reference Kojima, M., T. Ito, et al. 2005. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas 30: 1. Kojima, M., T. Ito, et al. 2005. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas 30: 1.
38.
go back to reference Usdin, T.B., T.I. Bonner, and E. Mezey. 1994. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135: 2662–2680.PubMedCrossRef Usdin, T.B., T.I. Bonner, and E. Mezey. 1994. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135: 2662–2680.PubMedCrossRef
39.
go back to reference Magistretti, P.J., P.R. Hof, et al. 1988. High- and low-affinity binding sites for vasoactive intestinal peptide (VIP) in the rat kidney revealed by light microscopic autoradiography. Regulatory Peptides 23: 145–152.PubMedCrossRef Magistretti, P.J., P.R. Hof, et al. 1988. High- and low-affinity binding sites for vasoactive intestinal peptide (VIP) in the rat kidney revealed by light microscopic autoradiography. Regulatory Peptides 23: 145–152.PubMedCrossRef
Metadata
Title
Vasoactive Intestinal Peptide Enhances TNF-α-Induced IL-6 and IL-8 Synthesis in Human Proximal Renal Tubular Epithelial Cells by NF-κB-Dependent Mechanism
Authors
Ling Huang
Yiting Tang
Jiao Qin
Yu Peng
Qiongjing Yuan
Fangfang Zhang
Lijian Tao
Publication date
01-06-2012
Publisher
Springer US
Published in
Inflammation / Issue 3/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9423-4

Other articles of this Issue 3/2012

Inflammation 3/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine